Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
- Wang, L.
- Zhou, T.
- Zhang, Y.
- Yang, E.S.
- Schramm, C.A.
- Shi, W.
- Pegu, A.
- Oloniniyi, O.K.
- Henry, A.R.
- Darko, S.
- Narpala, S.R.
- Hatcher, C.
- Martinez, D.R.
- Tsybovsky, Y.
- Phung, E.
- Abiona, O.M.
- Antia, A.
- Cale, E.M.
- Chang, L.A.
- Choe, M.
- Corbett, K.S.
- Davis, R.L.
- DiPiazza, A.T.
- Gordon, I.J.
- Hait, S.H.
- Hermanus, T.
- Kgagudi, P.
- Laboune, F.
- Leung, K.
- Liu, T.
- Mason, R.D.
- Nazzari, A.F.
- Novik, L.
- O&apos
- O&apos
- Olia, A.S.
- Schmidt, S.D.
- Stephens, T.
- Stringham, C.D.
- Talana, C.A.
- Teng, I.-T.
- Wagner, D.A.
- Widge, A.T.
- Zhang, B.
- Roederer, M.
- Ledgerwood, J.E.
- Ruckwardt, T.J.
- Gaudinski, M.R.
- Moore, P.L.
- Doria-Rose, N.A.
- Baric, R.S.
- Graham, B.S.
- McDermott, A.B.
- Douek, D.C.
- Kwong, P.D.
- Mascola, J.R.
- Sullivan, N.J.
- Misasi, J.
DOIAbstract
IC80 1.5 to 34.5 nanograms per milliliter). We define the structural and functional determinants of binding for all four VOC-targeting antibodies and show that combinations of two antibodies decrease the in vitro generation of escape mutants, suggesting their potential in mitigating resistance development.The emergence of highly transmissible SARS-CoV-2 variants of concern (VOCs) that are resistant to therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies. We identified four receptor binding domain-targeting antibodies from three early-outbreak convalescent donors with potent neutralizing activity against 23 variants, including the B.1.1.7, B.1.351, P.1, B.1.429, B.1.526, and B.1.617 VOCs. Two ant...
Add to ORKG